5.6.8. innovative treatment modalities. currently several potential novel treatment modalities ed. therapeutic approaches require investigation large-scale, blinded, placebo-controlled randomised studies achieve adequate evidence-based clinically-reliable recommendation grades [432-437]. 5.6.8.1. regenerative medicine therapies 5.6.8.1.1. shockwave therapy use low-intensity extracorporeal shock wave therapy (li-swt) increasingly proposed treatment vasculogenic ed last decade, itâ€™s currently marketed treatment might offer cure, desired outcome men suffering ed [328,438-445]. overall, several single-arm trials shown beneficial effect li-swt patient-reported ef, data prospective randomised trials conflicting, many questions remain answered due heterogeneity among shockwave generators, type shockwaves delivered, set-up parameters treatment protocols . trial trying assess best treatment parameters, significant differences observed various energy flux density levels; although, 0.10 mj/mm2 seems perform slightly better lower energies . studies suggested li-swt significantly increase iief ehs scores patients mild vasculogenic ed, although improvement appears modest rates patients reporting satisfactory improvement range 40-80% . studies shown improvement penile haemodynamic parameters li-swt, clinical meaning improvement remains unclear . likewise, data suggest li-swt could ameliorate erection quality even patients severe ed either pde5is non-responders inadequate responders , thus reducing immediate need invasive treatments. treatment effect appears clinically evident starting one three months treatment completion, subsequent progressive decrease achieved benefit terms ef time, although effects could still detected five years treatment . data rcts suggests even better results could achieved combining li-swt treatments ved men t2dm daily tadalafil . findings recent meta-analysis showed li-eswt positive effect early recovery ef context penile rehabilitation ed rp. however, authors clearly outlined level evidence low; therefore, careful interpretation results required [457-459]. 5.6.8.1.2. platelet-rich plasma intracavernous injection platelet-rich plasma (prp) investigated several prospective retrospective trials [460-466]. regenerative effect prp deemed exerted high concentrations platelets containing several growth factors including vegf, egf, igf-1, pdgf fgf . factors may responsible angiogenesis stimulation stem cell recruitment . first rct investigated effect intracavernous injection prp ed, 60 patients mild moderate vasculogenic ed randomised receive two injections 10 ml prp (n=30) placebo (n=30) . one, three six-month follow-up, rate patients reporting minimal clinically important difference (mcid) iief-ef score significantly higher treatment group, 69% achieving mcid six months prp vs. 27% placebo group (p < 0.001). iief-ef scores improved mean 2.7 points one-month 3.9 points six-month assessment treatment. regarding safety, haemorrhagic events side effects reported . prospective randomized, double-blind, placebo-controlled study carried 109 patients, aged 45-65 years, mild moderate ed, following cessation ed treatment . one, three six months prp injections, patients prp group significant improvement compared placebo terms iief-ef, sep2 sep3. moreover, six months post-treatment follow-up, 70% patients achieved mcid prp group compared 16% placebo group . even recently, prospective, randomized, double-blind, placebo-control study relatively small cohort mild moderate ed patients treated two prp injections separated one month showed treatment safe, authors find difference efficacy prp placebo . clinical relevance, patients allowed keep pde5is study . whole, despite number promising results obtained treatment primary organic ed terms efficacy safety prp, available evidence still insufficient provide recommendation regarding use prp ed treatment clinical practice . context, important heterogeneity among studies still exists terms timing dosing regimens, consensus regarding optimal activation method platelet concentration prp injection, need measure qualitative quantitative composition growth factors cytokines . therefore, intracavernous injection prp used clinical trial setting, larger trials needed confirm original findings define efficacy safety prp ed. 5.6.8.1.3. stem-cells use stem cells regenerative treatment ed currently investigation. systematic review concluded five completed human clinical trials shown promise stem cell therapy restorative treatment ed . however, data still insufficient providing clinical recommendation. 5.6.8.2. botulinum neurotoxin botulinum neurotoxin (bont-a) investigated possible ed treatment . two rcts investigated effect bont-a treatment patients ed non-responders pde5is ici pro-erectile drugs . one trial randomised 70 patients ed refractory pde5is receive single ici 100 ui bont-a saline . patients groups instructed keep using on-demand high-dose pde5is. rct showed improvement ehs psv two weeks post-treatment. six weeks treatment group showed 5 points improvement shim score vs. improvement placebo group, 53% patients reporting erection hard enough vaginal penetration . second trial randomised 176 patients, non-responders pde5is ici trimix, three treatment groups: bont-a 100 ui; bont-a 50 ui; placebo . significant improvement shim, ehs sep scores reported treatment groups maximum response rate reacted three months treatment. overall, rct showed 40% patients able resume satisfactory sexual activity treatment . trials reported mild local side-effects systemic complications. single-arm, non-controlled studies confirmed findings ; therefore, showing promising role bont-a treatment patients non-responders well-established ed therapies. however, present recommendation use clinical practice provided larger trials needed confirm original findings define efficacy safety bont-a ed.